Overview

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Status:
Active, not recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy. Phase 2 will be based on Simon's two-stage optimal design.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

ImmunityBio, Inc.
NantKwest, Inc.

Treatments:

Avelumab
Bevacizumab
Capecitabine
Cyclophosphamide
Fluorouracil
Leucovorin
Oxaliplatin
Paclitaxel
Vaccines